65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
Titel:
65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
Auteur:
Ma, J. Zhang, J. Yang, Y. Zheng, D. Wang, X. Liang, H. Zhang, L. Xin, Y. Ling, X. Fang, C. Jiang, H. Meng, H. Zheng, W.